Which two agents are approved for the treatment of both methicillin‑resistant Staphylococcus aureus (MRSA) and methicillin‑susceptible Staphylococcus aureus (MSSA) infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA-Approved Medications for Both MRSA and MSSA

Linezolid and daptomycin are the two agents FDA-approved for treatment of both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) infections.

Primary Recommendations

Based on IDSA guidelines, these two agents have distinct FDA approvals and clinical applications 1:

Linezolid

  • FDA-approved for: Skin and soft tissue infections (SSTI) and pneumonia caused by both MRSA and MSSA
  • Dosing: 600 mg PO/IV twice daily (adults); 10 mg/kg/dose every 8 hours in children <12 years (not to exceed 600 mg/dose)
  • Evidence level: AI/AII across multiple infection types 1
  • Route flexibility: Available in both oral and intravenous formulations, providing treatment continuity

Daptomycin

  • FDA-approved for: Complicated SSTI (4 mg/kg/dose IV daily) and bacteremia/right-sided endocarditis (6 mg/kg/dose IV daily) caused by both MRSA and MSSA
  • Evidence level: AI for complicated SSTI and bacteremia 1
  • Critical limitation: Cannot be used for pneumonia - daptomycin is inactivated by pulmonary surfactant 2

Clinical Context and Supporting Evidence

Recent research confirms daptomycin's rapid bactericidal activity and effectiveness as an alternative to vancomycin for MRSA or MSSA bacteremia and right-sided endocarditis 3. A 2014 review reinforces that daptomycin should be considered in patients with MRSA bacteremia and right-sided endocarditis as well as complicated SSSIs 2.

Important Caveats

Emerging resistance concerns: Recent 2026 data shows alarming resistance rates to linezolid (41% non-susceptibility) and concerning patterns with other agents, though daptomycin maintains 96.3% susceptibility 4. Multiple recent studies confirm daptomycin, linezolid, and vancomycin remain highly effective, with near-complete susceptibility in clinical isolates 5.

Other agents with activity but different approval status:

  • Vancomycin: While effective against both MRSA and MSSA, it is primarily indicated for MRSA (not specifically FDA-approved for MSSA when better alternatives exist)
  • Clindamycin: Has activity against both but faces resistance issues and is not universally approved for all MRSA infections
  • Telavancin: FDA-approved for complicated SSTI but less commonly used 1

Practical Application Algorithm

For complicated SSTI:

  • Either linezolid (600 mg PO/IV BID) OR daptomycin (4 mg/kg IV daily) 1

For bacteremia/endocarditis:

  • Daptomycin (6 mg/kg IV daily) is preferred 1
  • Linezolid is an alternative but with lower evidence level

For pneumonia:

  • Linezolid (600 mg PO/IV BID) - daptomycin is contraindicated 1

Duration: Typically 7-14 days for SSTI, individualized for bacteremia/endocarditis based on clinical response and source control 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.